This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary PD-L1 Therapeutic Antibody Development
Background of PD-L1
In the tumor microenvironment of companion animals, PD-L1 expression is often upregulated, allowing cancer cells to evade surveillance and attack by the immune system. This escape mechanism has led to the development of antibodies targeting PD-L1. BioVenic offers veterinary PD-L1 therapeutic antibody development services, covering the complete antibody development process, from initial animal immunization, antibody preparation, and screening to later stages of antibody characterization and validation, committed to assisting in finding solutions for the treatment of companion animal cancer.
Background of PD-L1
| Full Name | Programmed cell death 1 ligand 1 |
|---|---|
| Aliases | B7-H, B7H1, CD274, PDL1, PDCD1L1, PDCD1LG1. |
| Target Profile | PD-L1 is a transmembrane protein regarded as a co-inhibitory factor in immune responses, commonly expressed by macrophages, certain activated T cells and B cells, dendritic cells, and some epithelial cells, especially under inflammatory conditions. By binding with PD-1, PD-L1 plays an immunoregulatory role, typically leading to the suppression of T cell function and attenuation of immune responses. In cancer cells, the PD-1/PD-L1 axis inhibits T cell activation, proliferation, survival, and cytotoxic secretion, regulating the induction and maintenance of immune tolerance within the tumor microenvironment. |
MoA of PD-L1
When PD-1 interacts with its ligand PD-L1, it triggers phosphorylation of tyrosine residues in PD-1's ITSM domain. This action leads to the dephosphorylation of key kinases like Syk and PI3K, subsequently inhibiting the gene and cytokine activities essential for activating T cells. By overexpressing PD-L1, cancer cells can suppress the cytotoxic abilities of T cells, facilitating their evasion from immune responses. Predominantly, cancer cells enhance PD-L1 levels through activation of signaling pathways like EGFR, MAPK, or PI3K-Akt. This increased PD-L1 interacts with PD-1 on tumor-targeting CD8+ T cells, thereby hindering the immune system's ability to combat tumors. Moreover, the rise of inflammatory agents such as IFN-γ within the tumor microenvironment can further elevate PD-L1 and PD-L2 expression, leading to adaptive immune resistance.
Fig.1 Schematic diagram of PD-1/PD-L1-mediated inhibition of T cell activation. 1
Application in Veterinary Therapeutics
PD-L1 expression has been extensively studied in various canine tumors, including malignant melanomas, mammary tumors, osteosarcomas, hemangiosarcomas, mastocytomas, histiocytic sarcomas, renal cell carcinomas, lymphomas, and soft tissue sarcomas. PD-L1 is also expressed in feline squamous cell carcinoma, mammary cancer, fibrosarcoma, and renal cancer. Its expression on these tumor cells allows them to evade immune surveillance, reflecting the level of adaptive immune resistance of the tumor. Therefore, blocking the target PD-L1 may enhance the immune system's attack on tumor cells, and reveal the potential effectiveness of PD-L1 blockade strategies in certain canine tumor treatments.
Veterinary PD-L1 Therapeutic Antibody Development Services
By targeting PD-L1, it can potentially enhance the immune response in companion animals and provide more effective tumor therapies. Investigating the role of PD-L1 in companion animal tumors and therapeutic strategies is an important direction in animal health. BioVenic provides a one-stop service for the development of therapeutic antibodies against PD-L1 in veterinary medicine, which includes various stages of antibody preparation using diverse technologies, such as hybridoma technology, single B cell technology, and phage display technology, and subsequent structural and functional characterization services.
Please click the link below for more information about our veterinary PD-L1 therapeutic antibody development services.
Why Choose Us?
BioVenic provides a one-stop service, ensuring the quality and efficiency of the entire development process, from the initial antibody design and screening to subsequent production, purification, characterization, and functional validation.
Utilizing antibody engineering technologies such as affinity maturation and Fc engineering, our team optimizes the performance of the antibodies, reducing immunogenicity in companion animals, thereby enhancing the safety and effectiveness of the treatment.
We offer antibody development services for different animal species, such as canine and feline, ensuring the compatibility and efficacy of antibodies within specific species.
As an immunotherapy strategy, it is used to activate and enhance the immune system's response to tumors. PD-L1 targeted therapy has become a key component of the treatment for certain cancers. BioVenic offers veterinary PD-L1 therapeutic antibody development services to explore the therapeutic potential of PD-L1 in companion animal cancer. If you require more information about our services, please feel free to contact us!
References
- Chen, Xingyu, et al. "Mechanisms and strategies to overcome PD-1/PD-L1 blockade resistance in triple-negative breast cancer." Cancers 15.1 (2022): 104
- Maekawa, Naoya, et al. "Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors." PloS one 18.1 (2023): e0281143.